Ten Top Litigators to Lead ACIs Drug and Medical Device Litigation Advisory Board

Drug and Med Advisory Board members provide insights into the topics and trends in pharmaceutical and medical device products liability and guidance on the overall direction of the 19th Annual Drug and Medical Device Litigation Conference, December 8-10 in New York City.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

New York, New York (PRWEB) July 24, 2014

With great pleasure, American Conference Institute (ACI) announces the formation of its newly created Drug and Medical Device Litigation Conference Advisory Board. Comprised of a select group of industry leaders, the Advisory Board was created as a part of American Conference Institute’s ongoing effort to provide our audience with access to key experts in the field and industry-leading content for this flagship event, which averages over 400 attendees yearly.

ACI Drug and Med Advisory Board: http://drugandmed.com/board.html

Patricia A. Barbieri, Esq.
Deputy General Counsel, Litigation and Employment, Legal Affairs
Daiichi Sankyo, Inc. (Parsippany, NJ)

Donald P. Bunnin
Senior Litigation Counsel
Allergan, Inc. (Irvine, CA)

Debra L. Burns
Senior Counsel Litigation/Investigations
GE Healthcare (Wauwatosa, WI)

Jennifer Dubas
Vice President, Litigation & Risk
Endo Pharmaceuticals (Chadds Ford, PA)

Patrick L. Gibson
Director, Government Investigations
Merck & Co., Inc. (North Wales, PA)

Jill Harrison
Counsel
W.L. Gore (Flagstaff, AZ)

Rita A. McConnell
Vice President and Chief Litigation Counsel
Medtronic, Inc. (Minneapolis, MN)

Richard W. Silbert
V.P., Assoc. General Counsel
Purdue Pharma L.P. (Stamford, CT)

Lisbeth Warren
Assistant General Counsel
Johnson & Johnson (New Brunswick, NJ)

Mary-Alice Barrett
Assistant General Counsel, Senior Counsel Specialist- Litigation
Genentech (Little Falls, NJ)

Drug and Med Advisory Board members provide insights into the topics and trends in pharmaceutical and medical device products liability litigation and guidance on the overall direction of the conference program. Based on feedback from the Board, new topics to be discussed this year include:

  • Discovery Best Practices Post-Actos: Minimizing the Risk of Harsh Defense Sanctions in an MDL
  • Fighting Back Against Overbroad or No Injury Class Actions: Strategies for Drug and Medical Device Defense Counsel to Effectively Defeat Certification
  • Strategies for Preserving the Medical Device Preemption Defense Post-Stengel
  • Defending Against State AG Actions: Practical Considerations for Drug and Med Litigators Faced with an AG Action
  • Litigating in Difficult Jurisdictions: Winning the Knock Down Drag out Battle over Removal to State Court
  • and much more…

ACI is proud and privileged to work with the Board members in this ongoing collaboration to bring our delegates the finest and most relevant pharmaceutical and medical device products liability conferences.

Book your seat now and save $400 off of the full conference rate. Call 888-224-2480 or register online now.

For full details, visit: http://www.drugandmed.com/

ACI Drug and Med Advisory Board: http://drugandmed.com/board.html

View the full agenda and detailed information at http://drugandmed.com/agenda-glance.html

###

About ACI - American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world.

Staffed by industry specialists, lawyers and other professionals, American Conference Institute operates as a think tank, monitoring trends and developments in all major industry sectors, the law, and public policy, with a view to providing information on the leading edge.


Contact

Attachments